Rank |
Status |
Study |
1 |
Unknown †
|
Osteonecrosis in Children With Acute Lymphoblastic Leukemia
Conditions: |
Osteonecrosis; Acute Lymphoblastic Leukemia |
Intervention: |
|
Outcome Measures: |
Osteonecrosis 1 year post leukemia therapy; Bone mass density and Osteonecrosis; Is Bone loss/failure to accure bone mineral and ON; Glucocorticoid dose and ON; Methotrexate dose and ON; Obesity and ON; Weight bearing and non weight bearing activities and ON; Hyperlipidemia and On; Thrombophilia and ON |
|
2 |
Recruiting
|
Osteonecrosis of the Hip and Bisphosphonate Treatment
Condition: |
Osteonecrosis |
Interventions: |
Drug: Zoledronic Acid; Drug: Placebo |
Outcome Measures: |
reducing pain and disability in the hip; reducing progression to femoral head collapse and the need for surgical intervention |
|
3 |
Recruiting
|
Mesenchymal Stem Cells in Osteonecrosis of the Femoral Head
Condition: |
Avascular Necrosis of Femur Head |
Interventions: |
Biological: XCEL-MT-OSTEO-ALPHA; Procedure: Standard treatment |
Outcome Measures: |
Safety of XCEL-MT-OSTEO-ALPHA in Osteonecrosis of the femoral head; Feasibility of XCEL-MT-OSTEO-ALPHA in Osteonecrosis of the femoral head; Bone regeneration by measuring the necrotic angle using the modified Kerboul method; Dynamic changes of signal intensity; Clinical outcomes (pain) by Visual Analogue Scale (VAS); Clinical outcomes (SF-36); Clinical outcome (WOMAC) |
|
4 |
Recruiting
|
Phase 3 Study on Autologous Osteoblastic Cells Implantation to Early Stage Osteonecrosis of the Femoral Head
Condition: |
Osteonecrosis of the Femoral Head |
Interventions: |
Drug: Core decompression/PREOB® implantation; Drug: Core decompression/placebo implantation |
Outcome Measures: |
WOMAC VA3.1 pain subscale; Radiological progression to fractural stages, as demonstrated by conventional X-ray with reference to the ARCO Staging; Potential occurrence of any AE or SAE, related to the product or to the procedure, using patient open non-directive questionnaire, physical examination and laboratory measurements; WOMAC VA3.1; Time to arthroplasty |
|
5 |
Recruiting
|
Osteonecroses in Pediatric Patients With ALL
Conditions: |
Osteonecrosis; Acute Lymphoblastic Leukaemia; Lymphoblastic Lymphoma |
Intervention: |
|
Outcome Measures: |
occurence of early ON stages; ON incidence |
|
6 |
Unknown †
|
MBCP Safety and Performance in the Osteonecrosis of Femur Head
Condition: |
Osteonecrosis |
Intervention: |
Device: MBCP |
Outcome Measures: |
Infection and inflammation of the drilled area (blood and clinical assessment).; Adverse events.; Pain (Analogic Visual Scale); Hip function; Bone reconstruction evaluation through scanner and radiography |
|
7 |
Recruiting
|
PHASE II CLINICAL TRIAL Prospective, Open, Nonrandomized Treatment of Osteonecrosis of the Femoral Head by the Administration of Autologous Mesenchymal Stem Cells
Condition: |
Osteonecrosis of the Femoral Head |
Intervention: |
Procedure: bone marrow aspirate |
Outcome Measure: |
|
|
8 |
Recruiting
|
Study Into the Effect of Ibandronate for the Treatment of Bone Marrow Edema in Relation to Spontaneous or Non-traumatic Osteonecrosis of the Knee: A Randomized Double-blind, Placebo-controlled Trial
Conditions: |
Osteonecrosis of the Knee; Bone Marrow Edema of the Knee |
Interventions: |
Drug: Ibandronate IV; Drug: Placebo |
Outcome Measures: |
clinical outcome (pain [VAS score]); radiological outcome (MRI knee); number of salvage therapies needed in case persistence is observed during placebo therapy |
|
9 |
Recruiting
|
Osteonecrosis of the Jaw (ONJ) Case Registry
Condition: |
Osteonecrosis of the Jaw (ONJ) |
Intervention: |
|
Outcome Measures: |
Resolution rate and time to ONJ resolution; Explore the relationship between rate and time to ONJ resolution with ONJ severity and staging at Registry enrollment; Explore the relationship between rate and time to ONJ resolution with potential risk factors; Explore the relationship between rate and time to ONJ resolution and subsequent treatment patterns for ONJ; Explore the relationship between rate and time to ONJ resolution and treatment patterns of antiresorptive therapy |
|
10 |
Recruiting
|
Randomized Clinical Trial for the Treatment of Osteonecrosis of the Femoral Head
Condition: |
Osteonecrosis |
Intervention: |
Procedure: core decompression |
Outcome Measures: |
Magnetic Resonance Imaging (MRI); Visual Analog Scale (VAS); Harris Hip Score (HHS); Western Ontario and McMaster Universities Arthritis Index (WOMAC); Radiography (RX) |
|
11 |
Recruiting
|
Hyper Baric Oxygen Therapy (HBOT) for Spontaneous Osteonecrosis of the Knee
Condition: |
Spontaneous Osteonecrosis of the Knee |
Intervention: |
Biological: Weight reduction |
Outcome Measures: |
Efficacy; Safety; Reduction In AVN size by MRI |
|
12 |
Recruiting
|
Treatment of Medial Compartmental Osteoarthritis Grade 1-4 (Kellgren-Lawrence) or Osteonecrosis With TomoFix™ Small or Conservatively
Conditions: |
Osteoarthritis, Knee; Osteonecrosis |
Intervention: |
|
Outcome Measures: |
Knee Injury and Osteoarthritis Outcome Score (KOOS); Patient-evaluated function of the knee and quality of life, a. assessed with the Oxford-12-item knee score b. assessed with the WOMAC (as calculated from the KOOS); Clinician-evaluated function of the knee, assessed with the Japanese Orthopaedic Association (JOA) score; Health-related quality of life assessed by the generic Short Form-36 (SF-36) instrument; Range of motion (ROM); Local and general pain, assessed with the Visual Analogue Scale (VAS); Possibility and duration of the Japanese sitting style; Surgery details, Postoperative treatment, Postoperative rehabilitation, Utilization; Evaluation of degenerated and regenerated cartilage (arthroscopic findings assessed according to ICRS and Outerbridge / Koshino); Radiological parameters (e.g. union, delayed union, Kellgren-Lawrence classification, joint space narrowing, tibial slope, tibia vara, patella height according to Blackburne-Peel, modified Insall-Salvati ratio, subluxation of patella); Complications and mortality |
|
13 |
Recruiting
|
Bisphosphonate Biomarker Study
Conditions: |
Osteoporosis, With or Without Treatment; Bisphosphonate Treatment; Atypical Femur Fracture; Bisphosphonate Related Osteonecrosis of the Jaws (BRONJ); Healthy Volunteers |
Intervention: |
|
Outcome Measures: |
Absorption, Distribution, Metabolism, Excretion (ADME) Profiling of DNA from all sample types vs. normative data for the ADME panel and across study groups; Differential expression of miRNA biomarkers across participant groups within the study |
|
14 |
Not yet recruiting
|
Study Comparing Ibandronate Versus Placebo in Hip Osteonecrosis
Conditions: |
Aseptic;; Hip Necrosis |
Interventions: |
Drug: ibandronate; Drug: Placebo |
Outcome Measures: |
VAS pain; Imagery assessment; The Western Ontario and McMaster Universities Arthritis Index (Womac scale); Gait Analysis; Hip Harris score; Health-related quality of life EQ5D questionnaire |
|
15 |
Recruiting
|
Survey of XGEVA® Presrcibers in Europe to Evaluate Their Knowledge of the Summary of Product Characteristics Pertaining to Osteonecrosis of the Jaw
Conditions: |
Solid Tumours; Bone Metastasis |
Intervention: |
Other: Physician Survey |
Outcome Measure: |
Proportion of participating oncology practitioners prescribing XGEVA® who are aware of the SPC statements pertaining to ONJ (each question pertaining to a SPC statement will be assessed seperately at the end of each survey round) |
|
16 |
Not yet recruiting
|
Genetics in Predicting Risk of Bisphosphonate-Related Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid
Conditions: |
Malignant Neoplasm; Musculoskeletal Complications |
Interventions: |
Drug: zoledronic acid; Other: pharmacological study |
Outcome Measures: |
Plasma concentrations of Zol collected at visits 2, 3, 4, and 5; Urine concentrations of Zol collected at visits 2, 3, 4, and 5; Jawbone tissue concentrations of Zol collected during surgical treatment for BRONJ; Identify potential risk factors for BRONJ |
|
17 |
Recruiting
|
Focused Registry on the Conservative Treatment of Osteoarthritis of the Knee
Conditions: |
Osteoarthritis, Knee; Osteonecrosis |
Intervention: |
|
Outcome Measures: |
Function of the knee; Patient-evaluated function of the knee and quality of life; Clinician-evaluated function of the knee; Health-related quality of life; Range of motion (ROM); Local and general pain; Possibility and duration of the Japanese sitting style; Return to sport activities; Utilization; Evaluation of degenerated and regenerated cartilage; Radiological parameters; Complications; Anatomical alignment |
|
18 |
Unknown †
|
A Comparison of Two Different Surgical Techniques in Hip Resurfacing Arthroplasty
Conditions: |
Osteonecrosis; Femoral Neck Fracture; Implant Failure |
Intervention: |
Procedure: Surgical approach (ReCap Hip Resurfacing System) |
Outcome Measures: |
femoral head blood flow, evaluated by Laser Doppler Flowmetry; femoral head metabolism, evaluated by microdialysis; implant fixation, evaluated by RSA (radiostereogrammetric analysis); periprosthetic bone mineral density, evaluated by DEXA; gait function, evaluated by gait analysis; patient recovery, evaluated by Harris Hip Score and Visual Analogue Scale |
|
19 |
Recruiting
|
Oxford Signature vs. Conventional Global Study
Conditions: |
Osteoarthritis; Osteoarthritis, Knee; Osteonecrosis |
Interventions: |
Device: Signature Custom Guides; Procedure: Conventional Instrumentation |
Outcome Measures: |
Percentage of Knees Achieving Optimal Alignment; Average Number of Instrument Cases Used; Operative Time; Patient Satisfaction; Knee Function, Pain, and Range of Motion; Radiographic Outcomes; Tourniquet Time; Implant Sizing; Blood Loss; Transfusion Rate; Use of Cell-Saver; Number of Drains Used |
|
20 |
Recruiting
|
ACI-C Versus AMIC. A Randomized Trial Comparing Two Methods for Repair of Cartilage Defects in the Knee
Conditions: |
Osteochondritis Dissecans; Osteoarthritis; Cartilage Injury; Osteonecrosis |
Intervention: |
Procedure: Treatment of cartilage defects in the knee |
Outcome Measures: |
Perceived treatment efficacy as change from baseline in KOOS score; Change from baseline in radiological signs of arthritis progression; Perceived treatment efficacy as change from baseline in Lysholm score; Time to failure |
|